Regulation of anti-Müllerian hormone (AMH) in males and the associations of serum AMH with the disorders of male fertility

Hui-Yu Xu1,2,3,4,* , Hong-Xian Zhang5,* , Zhen Xiao6 , Jie Qiao1,2,3,4 , Rong Li1,2,3,4

Anti-Müllerian hormone (AMH) is a functional marker of fetal Sertoli cells. The germ cell number in adults depends on the number of Sertoli cells produced during perinatal development. Recently, AMH has received increasing attention in research of disorders related to male fertility. This paper reviews and summarizes the articles on the regulation of AMH in males and the serum levels of AMH in male fertility-related disorders. We have determined that follicle-stimulating hormone (FSH) promotes AMH transcription in the absence of androgen signaling. Testosterone inhibits the transcriptional activation of AMH. The undetectable levels of serum AMH and testosterone levels indicate a lack of functional testicular tissue, for example, that in patients with anorchia or severe Klinefelter syndrome suffering from impaired spermatogenesis. The normal serum testosterone level and undetectable AMH are highly suggestive of persistent Müllerian duct syndrome (PMDS), combined with clinical manifestations. The levels of both AMH and testosterone are always subnormal in patients with mixed disorders of sex development (DSD). Mixed DSD is an early-onset complete type of disorder with fetal hypogonadism resulting from the dysfunction of both Leydig and Sertoli cells. Serum AMH levels are varying in patients with male fertility-related disorders, including pubertal delay, severe congenital hypogonadotropic hypogonadism, nonobstructive azoospermia, Klinefelter syndrome, varicocele, McCune-Albright syndrome, and male senescence.

Asian Journal of Andrology (2019) 21, 109–114; doi: 10.4103/aja.aja_83_18; published online: 26 October 2018

Keywords: anti-Müllerian hormone; disorders related to male fertility; follicle-stimulating hormone; testosterone

INTRODUCTION TO AMH
Anti-Müllerian hormone (AMH), also known as Müllerian-inhibiting substance (MIS), is a Sertoli cell-secreted protein that plays a major role in the development of internal male genitalia.1 High expression of AMH in male gonads at the critical stage of embryonic genital development, i.e., 7 weeks of gestation,2–4 promotes regression of the Müllerian duct. In the absence of AMH, Müllerian ducts develop into female internal sex organs. Anti-Müllerian hormone is named based on these processes. AMH is a dimeric glycoprotein consisting of two identical 70-kDa subunits and constitutes the transforming growth factor-beta (TGF-β) superfamily together with inhibins, activins, bone morphogenetic proteins (BMPs), and growth differentiation factors (GDFs). TGF-β family members play important roles in the regulation of spermatogenesis induced by high concentrations of intratesticular testosterone.

ROLE OF AMH IN SERTOLI CELL PHYSIOLOGY
Sertoli cells are the earliest cell type that appear in the embryonic testis.4,5 More than 75% of the gonadal mass in the prepubertal testis is composed of Sertoli cells.5,6 Dysfunction of Sertoli cell proliferation or maturation may lead to secretory dysfunction via endocrine and paracrine signaling, leading to an inability to support spermatogenesis. During fetal life, AMH is exclusively secreted by Sertoli cells and can be used as a functional marker of fetal Sertoli cells.7 Sertoli cells secrete other proteins that include (1) inhibins and activins, which are secreted by adult Sertoli cells to regulate follicle-stimulating hormone (FSH) production; (2) androgen-binding proteins (ABPs), which act as carrier proteins of testosterone and are responsible for the high concentration of intratesticular testosterone necessary for spermatogenesis;8 (3) estradiol, which is transformed from testosterone catalyzed by aromatases in Sertoli cells; and (4) glial cell line-derived neurotrophic factors (GDNFs), which contribute to the self-renewal of spermatogonial stem cells. All of these factors secreted by Sertoli cells are involved in spermatogenesis. 9–11 Furthermore, Sertoli cells, rather than germ cells, express the androgen receptor,11 which is critical for the regulation of spermatogenesis induced by high concentrations of intratesticular testosterone.12

FSH is responsible for AMH transcriptional activation and the increase of Sertoli cell number in the absence of androgen signaling
The germ cell number in adult men depends on the number of Sertoli cells produced during perinatal development.13,14 FSH has...
been recognized as a regulator of Sertoli cell number in developing testes.\textsuperscript{14,15} The hypothalamic–pituitary–gonadal (HPG) axis is inactive in prepuberty, as demonstrably by low levels of both testosterone and gonadotropins.\textsuperscript{1,6–19} Lukas-Croisier \textit{et al}.\textsuperscript{20} used a prepubertal FSH-deficient (FSH\textsuperscript{-/-}) transgenic male mouse model to demonstrate that FSH transcriptionally activates AMH production in the absence of androgen signaling. They showed that serum AMH concentration, Sertoli cell number, and testicular volume were decreased in FSH knockout mice and returned to normal after administration of recombinant FSH and transfection of FSH receptor plasmid. They next transfected different fragments of AMH promoters, together with the FSH receptor gene, into a prepubertal Sertoli cell line and added recombinant FSH protein to activate AMH transcription. The results showed that FSH transcriptionally activates AMH through a nonclassical cyclic adenosine monophosphate (cAMP) pathway by binding to the AMH promoter region located more than -1.9 kb away from the transcription initiation site at nuclear factor kappa-B (NF-kB) and transcription factor AP2-binding sites.\textsuperscript{20} Unlike the distal regulation of the AMH promoter region by NF-kB, regulation of the proximal promoter of AMH has been extensively studied.

The hypothalamic–pituitary–gonadal (HPG) axis is inactive within -220 bp of the transcriptional start site independent of gonadotropic control.\textsuperscript{28,29} A schematic diagram of FSH-regulated AMH transcriptional activation is shown in Figure 1. Another study using Tm mice with a mutation in the androgen receptor gene that made the XY mouse insensitive to androgens\textsuperscript{20,21} showed that FSH administration resulted in the elevation of serum AMH levels in the absence of androgen signaling.\textsuperscript{23} FSH-induced AMH transcription and an increase in Sertoli cell number were also observed in neonates and adult humans suffering from hypogonadotropic hypogonadism (HH).\textsuperscript{24,25,31} The androgen signaling pathway of these individuals is not functional, and their decreased AMH levels return to normal after the administration of recombinant FSH.

\textbf{Testosterone downregulates AMH expression}

The most obvious example of negative regulation of AMH by testosterone is that when boys enter puberty, a sudden increase in their testosterone levels results in decreased levels of AMH, indicating that testosterone has an inhibitory effect on AMH;\textsuperscript{24} the increased intratesticular testosterone levels is responsible for the inhibition of AMH levels.\textsuperscript{32,33–37} Another example is the increase in testosterone levels in precocious children, which is always accompanied by a decrease in AMH levels regardless of gonadotropic dependence or independence.\textsuperscript{19} This negative regulatory pattern can also explain hormone levels in patients with androgen insensitivity syndrome (AIS) caused by mutations in the androgen receptor gene. The diagnosis of AIS is made by detecting normal-to-high testosterone and AMH levels and the absence of Müllerian derivatives in 46,XY males.\textsuperscript{28,30–34} the high levels of testosterone do not induce a decrease in AMH levels due to androgen signaling dysfunction.

Animal experiments also revealed a pattern of negative regulation between testosterone and AMH. The knockout of androgen receptors in Sertoli cells in mice induces a significant decrease in testosterone levels and thus gives rise to transiently elevated expression of AMH at both the mRNA and protein levels in Sertoli cells.\textsuperscript{41} How does testosterone inhibit the expression of AMH? Another study performed the following mechanistic investigation to show that binding at the NF-kB-binding site in the distal promoter region of AMH provides transcriptional activity levels higher than those produced by binding at the SP1-, GATA-, and Sox9-binding sites in the proximal promoter regions.\textsuperscript{20} Although there are no androgen receptor-binding sites in the AMH promoter region,\textsuperscript{42} there are NF-kB binding sites, and NF-kB is negatively regulated by androgen receptors;\textsuperscript{43,44} therefore, although testosterone cannot directly regulate AMH transcription, it can fulfill its function by inhibiting the transcription of NF-kB and thus suppress the transcriptional activation of AMH.

However, AMH levels are not always negatively regulated by testosterone because of defects in androgen signaling. For instance, a synchronous increase in AMH and testosterone levels was discovered in neonates.\textsuperscript{40–42} It was discovered that the androgen receptor is present in fetal and neonatal Leydig and peritubular cells but not in Sertoli cells.\textsuperscript{46,47} The absence of androgen receptor expression in fetal and neonatal Sertoli cells may contribute to the lack of transcriptional suppression of AMH. Thus, FSH-induced AMH transcriptional activation and luteinizing hormone (LH)-induced testosterone activation account for the main biological events in fetal and neonatal boys.

\textbf{ASSOCIATIONS BETWEEN SERUM AMH AND DISORDERS RELATED TO MALE FERTILITY}

\textbf{Diagnosis and differential diagnosis of disorders of sex development (DSD)}

Male genital differentiation is driven by two hormones: testosterone, which is produced by fetal Leydig cells, maintains Wolffian ducts, and contributes to the virilization of external genitalia, and AMH, which is produced by fetal Sertoli cells and is responsible for the regression of fetal Müllerian ducts.\textsuperscript{48} DSD in males may result from defects in the signaling of one or both of these hormones. Dysfunction of secretion or an inactive state of AMH, caused by mutations in \textit{AMHRII}, leads to persistent Müllerian duct syndrome (PMDS). Patients with PMDS are born male according to the general human standard at birth, but the Müllerian duct derivatives persist, manifested as undescended testes (cryptorchidism) and the presence of a small, underdeveloped uterus in an XY infant or adult. Notably, fertility in PMDS patients is rare but possible if at least one testis descends to the scrotum with its excretory ducts intact.\textsuperscript{49} No external genital ambiguity, especially without hypospadias, is the main feature of PMDS that distinguishes it from mixed gonadal dysgenesis, which is an early-onset complete type of DSD with fetal hypogonadism resulting from the dysfunction of both Leydig and Sertoli cells.\textsuperscript{28}
Recently, mutations in the AMH and its receptor gene were found to account for 88% of PMDS cases in which undescended testes (UDTs) are the clinical manifestation. The remaining 12% of PMDS cases are idiopathic, and no mutations in AMH or AMHRII have been detected. However, we cannot rule out the possibility of AMH or AMHRII mutations, as some studies have shown that the diversity of AMH or AMHRII mutations might be underestimated and that the sensitivity and specificity of sequencing can be limited, leading to unidentified mutations in the distal promoter or introns of AMH or AMHRII. Furthermore, we cannot rule out the possibility of mutations in other molecules in the AMH signaling pathway.

PMDS should be distinguished from other types of UDT. Leydig cell function in patients with PMDS is generally normal, as indicated by normal levels of serum testosterone and LH. The levels of inhibin B, secreted by Sertoli cells, are normal in boys with AMH mutations but undetectable in boys with AMHR II mutations. Serum AMH levels depend on the molecular origin of AMH or AMHRII mutations. Very low or undetectable circulating AMH levels in prepubertal boys or adults with PMDS are characteristics of mutations in AMH, resulting in a lack of AMH protein secretion. Meanwhile, normal serum AMH levels are detected in boys with AMHR II mutations.

Congenital adrenal hyperplasia (CAH) in females (46,XX) with a male phallus and bilateral nonpalpable gonads should first be differentially diagnosed from UDT via its severe complications, such as hyponatremia, hyperkalemia, and shock. When increasing severity of hypospadias with UDT is discovered, the possibility of a mixed DSD should be considered. In patients with mixed types of DSD accompanied by low serum levels of both AMH and testosterone and external genital malformations, low AMH reflects severe testicular dysgenesis and should not be confused with PMDS. If an infant with bilateral nonpalpable testes has a 46,XY karyotype, an evaluation to distinguish anorchia from bilateral AMHRII mutations, as some studies have shown that the diversity of AMH or AMHRII mutations might be underestimated and that the sensitivity and specificity of sequencing can be limited, leading to unidentified mutations in the distal promoter or introns of AMH or AMHRII. Furthermore, we cannot rule out the possibility of mutations in other molecules in the AMH signaling pathway.

PMDS should be distinguished from other types of UDT. Leydig cell function in patients with PMDS is generally normal, as indicated by normal levels of serum testosterone and LH. The levels of inhibin B, secreted by Sertoli cells, are normal in boys with AMH mutations but undetectable in boys with AMHR II mutations. Serum AMH levels depend on the molecular origin of AMH or AMHRII mutations. Very low or undetectable circulating AMH levels in prepubertal boys or adults with PMDS are characteristics of mutations in AMH, resulting in a lack of AMH protein secretion. Meanwhile, normal serum AMH levels are detected in boys with AMHR II mutations.

Congenital adrenal hyperplasia (CAH) in females (46,XX) with a male phallus and bilateral nonpalpable gonads should first be differentially diagnosed from UDT via its severe complications, such as hyponatremia, hyperkalemia, and shock. When increasing severity of hypospadias with UDT is discovered, the possibility of a mixed DSD should be considered. In patients with mixed types of DSD accompanied by low serum levels of both AMH and testosterone and external genital malformations, low AMH reflects severe testicular dysgenesis and should not be confused with PMDS. If an infant with bilateral nonpalpable testes has a 46,XY karyotype, an evaluation to distinguish anorchia from bilateral AMHRII mutations, as some studies have shown that the diversity of AMH or AMHRII mutations might be underestimated and that the sensitivity and specificity of sequencing can be limited, leading to unidentified mutations in the distal promoter or introns of AMH or AMHRII. Furthermore, we cannot rule out the possibility of mutations in other molecules in the AMH signaling pathway.

Studies of unilateral UDT revealed that UDTs in children are smaller than their descended counterparts (P < 0.001). Given that Sertoli cells account for 75% of testis mass in prepubertal males, there may be varying degrees of decline in the number of Sertoli cells in UDT, which may result from increased temperature around the UDT. The degree of AMH decrease in boys bearing cryptorchidism is related to the severity of UDT injury, suggesting that deteriorated Sertoli cell function may be an early example of damage from UDT. Moreover, infertility is the major long-term concern of patients with a history of UDT. Infertility risks of 30% and 54% were discovered in unilateral and bilateral UDT, respectively, in accordance with the duration for which UDT is exposed to abdominal temperature. A 75%–100% risk of infertility was found in boys with bilateral UDT in whom no germ cells were found on biopsy. In conclusion, the degree of male infertility caused by UDT is related to the severity of injury to Sertoli cells; thus, a higher degree of serum decline in AMH in boys may suggest a greater risk of infertility when they become adults.

Distinguishing pubertal delay from congenital hypogonadotropic hypogonadism

Constitutional pubertal delay and congenital HH share the same clinical manifestation of delayed sexual maturation in prepubertal boys. Levels of gonadotropin and testosterone are very low in prepubertal boys and therefore have little clinical significance; thus, AMH, the marker of Sertoli cells, is of great importance in the differential diagnosis of constitutional pubertal delay and congenital HH.

Congenital HH is often accompanied by Sertoli cell dysfunction. Severe deficiency in gonadotropin levels in congenital HH patients results in a decreased number of Sertoli cells and correspondingly low levels of AMH and inhibin B. The constitutional delay of puberty reflects a eugonadal state of Sertoli cells, and serum AMH is within the normal level for prepubertal boys. In patients with untreated congenital HH, the AMH level is increased upon administration of recombinant FSH due to FSH-induced proliferation of Sertoli cells, whereas further treatment with human chorionic gonadotropin (hCG) gives rise to a decline in AMH levels due to the hCG-induced increased levels of testosterone, which induces inhibition of AMH that overrides FSH-initiated AMH transcription. However, the administration of exogenous testosterone did not result in a decrease in AMH concentrations, which may be caused by low intratesticular testosterone levels in congenital HH patients.

Nonobstructive azoospermia and Klinefelter syndrome (47,XXY)

Nonobstructive azoospermia (NOA) is the most severe type of male infertility, characterized by a lack of sperm in semen induced by impaired spermatogenesis. Increased serum FSH, decreased serum AMH and inhibin B, have been discovered in men with NOA. With the advent of intracytoplasmic sperm injection (ICSI) technology, these NOA patients also have the opportunity to have their own children through testicular sperm extraction (TESE) or microdissection-testicular sperm extraction (MD-TESE), with sperm recovery rates (SRRs) of only 40%–60%. Currently, there are no acknowledged markers of SRR with good sensitivity and specificity. FSH, inhibit B, AMH, and testosterone, although differentially expressed in NOA, are not good predictors of SRR. Higher baseline testosterone, lower FSH, higher AMH, or higher inhibin B levels do not guarantee a better SRR in NOA patients. The underlying mechanism may be the following: the function of the Sertoli cells...
and interstitial cells is impaired, as indicated by abnormal hormone levels, but not completely lost in a large number of NOA patients; spermatogenesis is only present in small areas, if any. In our clinical practice, we have identified a certain number of NOA patients whose serum AMH levels are below the lower limit of the male reference interval or even undetectable and whose serum testosterone levels are normal or subnormal yet obtain good pregnancy outcomes using their own sperm retrieved via TESE or MD-TESE. These serum markers may be useful when combined with testicular volume, age and other markers to predict SRR before TESE or MD-TESE using a multivariable regression method.

Klinefelter syndrome is characterized by accelerated germ cell depletion and occurs in approximately 10%–12% of NOA men. In patients with Klinefelter syndrome, circulating AMH levels are within the reference range until puberty; thereafter, AMH declines to subnormal concentrations in adults. In a 12.3-year follow-up study of 29 patients with Klinefelter syndrome, an early increase in FSH was detected, accompanied by abnormally low or undetectable levels of AMH and inhibin B in advanced pubertal stages, which may be explained by progressive impairment of endocrine function during childhood and puberty. However, a delay in the puberty-related decline of AMH was observed in patients with Klinefelter syndrome, finally leading to decreased AMH levels in adulthood, which may be caused by temporary functional compensation of Sertoli cells. Furthermore, in our clinical practice, we identified a few severe NOA patients, including severe Klinefelter syndrome patients, whose serum AMH and testosterone levels were both undetectable and with no sperm retrieved via MD-TESE, indicating that their germ cells were completely depleted. Undetectable AMH and testosterone were also used to distinguish anorchia from UDT, as shown in Figure 2, implying that in male adults, undetectable serum AMH and testosterone can be used to assess whether any functional testicular tissue or, specifically, functional germ cells exist.

**Varicocele**

Varicocele is an abnormal enlargement and bending of the pampiniform venous plexus in the scrotum. The adverse effects of varicocele on spermatogenesis are progressive and therefore decrease male fertility with time. Expansion of the veins impairs the testicular blood supply, resulting in a reduction in the oxygenated blood and nutrient supply to the local testes, which leads to a decline in the quality and quantity of sperm; on the other hand, it also induces dysfunction of the testicular nervous plexus, the main function of which is to regulate testicular temperature. Higher testicular temperatures can lead to testicular atrophy and infertility. Indeed, varicocele is the main cause of male infertility and it was found in approximately 35% of primary infertile men and 81% of secondary infertile men.

The severe damage caused by varicocele is correlated with impaired function of Sertoli cells. According to the study from Li et al., the levels of transferrins and androgen-binding proteins secreted by Sertoli cells were reported to be downregulated in patients suffering from varicocele, suggesting that decreased testicular blood flow may lead to impaired function of Sertoli cells. Furthermore, testicular biopsies in patients with varicocele showed that the germ cells in the seminiferous tubule were sloughed, and this phenomenon was often associated with impaired Sertoli cell function.

An analysis of serum AMH levels in varicocele-bearing patients was inconclusive. A study in adult subfertility men including varicocele, idiopathic NOA, idiopathic nonobstructive dyspermia, cryptorchidism, and other diagnoses indicated that circulating AMH levels in subfertile men were 60% lower than those in corresponding controls, accompanied by a decreased level of inhibin B, indicating the decreased function of Sertoli cells in varicocele-bearing adult patients. In prepubertal and pubertal boys with varicocele, AMH concentrations were elevated, accompanied by an increase in inhibin B levels, suggesting a compensatory increase in Sertoli cell function in the early-onset varicocele. There was also an article reporting a lower concentration of AMH in the local spermatic vein than in the peripheral blood, suggesting that poor blood supply in patients with varicocele causes the deterioration of Sertoli cell function.

**McCune-Albright syndrome in boys**

As we mentioned previously, normal puberty is accompanied by decreased serum levels of AMH. However, in boys with McCune-Albright syndrome, precocious puberty is observed, but abnormal increased instead of decreased levels of AMH are detected, accompanied by macro-orchidism and androgen-dependent secondary sexual defects. Hyperfunction of Sertoli cells without Leydig cell activation was reported to be responsible for the onset of this disease.

**Male senescence**

Testes, hormone production, and spermatogenesis undergo senescence as a man ages. Johnson et al. identified an age-related decrease in Sertoli cell number; consistent with this, AMH, as a marker of Sertoli cell function, was also found to be reduced with increasing age and negatively correlated with FSH and LH, which indicates that decreased AMH levels as a man ages represent age-related reduced Sertoli cell function.

**CONCLUSION**

In the absence of androgen signaling, FSH promotes AMH transcription by activating the -1.9 kb AMH promoter region, where NF-kB has the highest level of transcriptional activation activity, and the proximal within -220 bp AMH promoter region, where Sox9, SFP1, and GATA factors reside. Testosterone inhibits the transcriptional activation of AMH, hypothetically through transcriptional inhibition of NF-kB. Regarding the associations between serum AMH and disorders related to male fertility, undetectable serum AMH and testosterone indicate a lack of functional testicular tissue, for example, that in patients with anorchia or severe Klinefelter syndrome suffering from impaired spermatogenesis. Normal serum testosterone levels and

| Table 1: Anti-Müllerian hormone levels in disorders related to male fertility |
|-----------------------------------------------|
| Categories                  | AMH level                                    |
|-------------------------------|-----------------------------------------------|
| Pubertal delay                | Normal prepubertal level in puberty           |
| Severe congenital HH          | Decreased in puberty                          |
| Klinefelter syndrome (47,XY)  | Within the reference range until puberty; a delay in puberty-related decline, thereafter, declined to subnormal concentrations in adults |
| NOA                           | Decreased AMH level                           |
| Varicocele                    | Elevated in early-onset varicocele in prepubertal and pubertal boys, and decreased in adults with severe varicocele |
| McCune-Albright syndrome      | Increased AMH level in boys                   |

HH: hypogonadotropic hypogonadism; NOA: nonobstructive azoospermia; AMH: anti-Müllerian hormone.
undetectable AMH are highly suggestive of PMDS. The levels of both AMH and testosterone are always subnormal in patients with mixed DSD (as shown in Figure 2). The usefulness of AMH levels in these conditions (pubertal delay, severe congenital HH, NOA, Klinefelter, varicocele, McCune-Albright syndrome, and male sexenesscence) is also summarized, as indicated in Table 1.

AUTHOR CONTRIBUTIONS

HYX and HXZ participated in the study design and references collection, and most of the manuscript writing. ZXP participated in Figures drawing. JQ conceived the study. RL conceived and designed collection, and most of the manuscript writing. ZX participated in transcription of the human anti-Müllerian hormone gene.

Direct interaction of SRY-related protein SOX9 and steroidogenic factor 1 regulates the Müllerian inhibiting substance gene: a link to the sex determination cascade. Cell 1994; 77: 651–61.

Guiu G, Shen WH, Ingham HA. The nuclear receptor steroidogenic factor 1 regulates the Müllerian inhibiting substance gene: a link to the sex determination cascade. Cell 1994; 77: 651–61.

Watanabe K, Clarke TR, Lane AH, Wang X, Donahoe PK. Endogenous expression of Müllerian inhibiting substance in early postnatal rat sertoli cells requires multiple steroidogenic factor-1 and GATA-4-binding sites. Proc Natl Acad Sci U S A 2000; 97: 1624–9.

Tremblay JJ, Viger RS. Transcription factor GATA-4 enhances Müllerian inhibiting substance gene transcription through a direct interaction with the nuclear receptor SF-1. Mol Endocrinol 1999; 13: 1388–401.

Beau C, Rauch M, Joulvin V, Jegou B, Guerrier D. GATA-4 is a potential repressor of anti-Müllerian hormone expression during the establishment of puberty in the mouse. Mol Reprod Dev 2000; 56: 124–38.

Rey RA, Grinspon RP. Normal male sexual differentiation and aetiology of disorders of sex development. Best Pract Res Clin Endocrinol Metab 2011; 25: 221–38.

Rey R, Lukas-Croisier C, Lasala C, Bedecarras P. AMH/MIS: what we know already about the gene, the protein and its regulation. Mol Cell Endocrinol 2003; 211: 21–31.

Lyon MF, Hawkes SG. X-linked gene for testicular feminization in the mouse. Nature 1970; 227: 1217–9.

Caresti NJ, Zhou ZX, Lubahn DB, Olsen EM, Wilson EM. A framework mutation destabilizes androgen receptor messenger RNA in the Tfm mouse. Mol Endocrinol 1991; 5: 573–81.

Al-Attar L, Noel K, Dutertre M, Belville C, Forest MG, et al. Hormonal and cellular regulation of sertoli cell anti-Müllerian hormone production in the postnatal mouse. J Clin Invest 1997; 100: 1353–45.

Bougneres P, Francois M, Pantalone L, Rodrigue D, Bouvattier C, et al. Effects of an early postnatal treatment of hypogonadotrophic hypogonadism with a continuous subcutaneous infusion of recombinant follicle-stimulating hormone and lutetinizing hormone. J Clin Endocrinol Metab 2008; 93: 2202–5.

Rey R, Lordereau-Richard C, Carel JC, Barbet P, Cate RL, et al. Anti-müllerian hormone and testosterone serum levels are inversely during normal and precocious pubertal development. J Clin Endocrinol Metab 1993; 77: 1220–6.

Young J, Rey R, Couzinnet B, Chanson P, Jossou N, et al. Anti-Müllerian hormone in patients with hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1999; 84: 2696–9.

Aksiglade L, Sorensen K, Boas M, Mouritsen A, Hagen CP, et al. Changes in anti-Müllerian hormone (AMH) throughout the life span: a population-based study of 1027 healthy males from birth (cord blood) to the age of 69 years. J Clin Endocrinol Metab 2010; 95: 5357–64.

Grinspon RP, Bedecarras P, Ballerini MG, Iniguez G, Rocha A, et al. Early onset of primary hypogonadism revealed by serum anti-Müllerian hormone determination during infancy and childhood. Arch Dis Child 2011; 34: e487–98.

Jossou N, Rey R, Picard JY. Testicular anti-Müllerian hormone: clinical applications in DSD. Semin Reprod Med 2012; 30: 364–73.

Werner R, Grotsh H, Hiort O. 46,XY disorders of sex development – the undermasculinised male with disorders of androgen action. Best Pract Res Clin Endocrinol Metab 2010; 24: 263–77.

Bukhari I, Li G, Wang L, Jigal F, Zhang H, et al. Effects of androgen receptor mutation on testicular histopathology of patient having complete androgen insensitivity. J Mol Histol 2017; 48: 159–67.

Chang C, Chen YT, Yeh SD, Xu Q, Wang RS, et al. Infertility with defective spermatogenesis and hypotestosteronemia in male mice lacking the androgen receptor in sertoli cells. Proc Natl Acad Sci U S A 2004; 101: 6871–81.

Rey R, Jossou N. Regulation of testicular anti-Müllerian hormone secretion. Eur J Endocrinol 1996; 135: 144–52.

McKay LI, Cidlowski JA. Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: mechanisms of mutual antagonism. Mol Endocrinol 1998; 12: 45–56.

Corbier P, Edwards DA, Roffi J. The neonatal testosterone surge: a comparative study. Arch Int Physiol Biochim Biophys 1992; 100: 127–31.

Matuszczak E, Hermanowicz A, Komarowska M, Debek W. Serum AMH in physiology and pathology of male gonads. J Endocrinol Endocrinol 2013; 2013: 1298097.

Chemes HE, Rey RA, Jostal M, Regadera J, Musse M, et al. Physiological androgen insensitivity of the fetal, neonatal, and early infantile testis is explained by the ontogeny of the androgen receptor expression in sertoli cells. J Clin Endocrinol Metab 2008; 93: 4408–12.

Jos A. Problems of fetal endocrinology: the gonadoblastoma and hypothyroidism. Recent Prog Horm Res 1953; 8: 379–418.
Asian Journal of Andrology
199
58
57
54
50
77
75
74
69
68
67
62
61
45
38
37
36
35
34
33
32
31
30
29
28
27
26
25
24
23
22
21
20
19
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
0

Engeler DS, Hosli PO, John H, Bannwart F, Sulser T, et al. Long-term testicular volume after orchiopexy at diagnosis of acquired undescended testis. J Urol 2013; 190: 257–62.

Matusczak E, Hermanowicz A, Debek W, Oksiuta M, Dzienis-Koroknieczew I, et al. Serum AMH concentration as a marker evaluating gonadal function in boys operated on for unilateral cryptorchidism between 1st and 4th year of life. Endocrine 2012; 41: 334–8.

Demircan M, Akinci A, Mutus M. The effects of orchopexy on serum anti-Müllerian hormone levels in unilateral cryptorchid infants. Pediatr Surg Int 2006; 22: 271–3.

Guibourdenc J, Lucidarme N, Chevennne D, Rigal O, Nicolas M, et al. Anti-Müllerian hormone levels in serum from human foetuses and children: pattern and clinical relevance. Mol Cell Endocrinol 2003; 211: 55–63.

Cortes D. Cryptorchidism-aspects of pathogenesis, hormone levels, and histopathology. Scand J Urol Nephrol Suppl 1998; 1: 54.

Engeler DS, Hosli PO, John H, Bannwart F, Sulser T, et al. Long-term testicular volume after orchiopexy at diagnosis of acquired undescended testis. J Urol 2013; 190: 257–62.

Lee MM, Misra M, Donahoe PK, MacLauchlin DT: MIS/AMH in the assessment of cryptorchidism and intersex conditions. Mol Cell Endocrinol 2003; 211: 91–8.

Stoppa-Vaucher S, Djemli A, Van Viet G. Undetectable AMH at 3 days of age: a clue to bilateral anorchia. Clin Biochem 2010; 43: 1373–4.

Szarras-Czapnik M, Gajewska M, Ksiazek J, Janas R, Ginalska-Malinska W. Anti-Müllerian hormone (AMH) measurements in the assessment of testicular function in prepubertal boys and in sexual differentiation disorders. Endokrynol Plod Zrnezyni Materi Wieku Rzow 2006; 12: 195–9. [Article in Polish].

Redmon JB, Carey P, Pryor JL. Varicocele—the most common cause of male factor infertility? Hum Reprod Update 2002; 8: 53–8.

Gorelick JI, Goldstein L. Loss of fertility in men with varicocele. Fertil Steril 1993; 59: 613–4.

Li H, Dubocq F, Jiang Y, Tigert R, Gheler EL, et al. Effects of surgically induced varicocele on testicular blood flow and spermatozoa cell function. Urology 1999; 53: 1258–62.

Cameron DF, Snydle FE, Ross MH, Drylie DM. Ultrastuctural alterations in the adluminal compartment of the testis in men with varicocele. Fertil Steril 1980; 33: 526–33.

Gouilh DG, Haidou PK, Tsametis C, Gerou S, Tarlatzis BC, et al. Serum anti-Müllerian hormone levels differentiate control from subfertile men but not with men with different causes of subfertility. Gynecol Endocrinol 2008; 24: 158–60.

Trigo RV, Bergada I, Rey R, Ballerini MG, Bedecarras P, et al. Altered serum profile of inhibin B, Pro-alphaC and anti-Müllerian hormone in prepubertal and pubertal boys with varicocele. Clin Endocrinol (Oxf) 2004; 60: 758–64.

Goupil D, Mintsiori G, Koliakos N, Hatzichristou D, Papadimas I, et al. Inhibin B and anti-Müllerian hormone in spermatic vein of subfertile men with varicocele. Hum Reprod Sci 2011; 18: 551–5.

Voigt TM, Dorr HG. McCune-Albright syndrome: clinical picture and natural history in children and adolescents. J Pediatr Endocrinol Metab 2006; 19 Suppl 2: S51–9.

Coutaud Y, Lumbroso S, Rey R, Lahlou N, Venara S, et al. Macroorchidism due to autonomous hyperfunction of somatotroph cells and GSIalpha gene mutation: an unusual expression of McCune-Albright syndrome in a prepubertal boy. J Clin Endocrinol Metab 2001; 86: 1778–81.

Manikin I, Philibert P, Anhalt H, Ten S, Sultan C. Unusual phenotypical variations in a boy with McCune-Albright syndrome. Horm Res Paediatr 2010; 73: 215–22.

Rey RA, Venara M, Coutant R, Trabut JB, Rouleau S, et al. Unexpected mosaicism of R201H-GNAS1 mutant-bearing cells in the testes underlie macro-orchidism without sexual precocity in McCune-Albright syndrome. Hum Mol Genet 2001; 10: 3538–43.

Gunes S, Hekim GN, Arslan MA, Ascì R. Effects of aging on the male reproductive system. J Assist Reprod Genet 2016; 33: 441–5.

Johnson L, Petty CS, Neaves WB. Age-related variation in seminiferous tubules in men. A stereologic evaluation. J Androl 1986; 7: 316–22.

Chong YH, Dennis NA, Connolly MJ, Teh R, Jones GT, et al. Effects of aging in healthy adult Iranian men: a population-based study. PLoS One 2017; 12: e0179634.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

©The Author(s)(2018)